Prognostic significance of clinic pathological and selected immunohistochemical factors in endometrial cancer;Prognostický význam klinickopatologických a vybraných imunohistochemických faktorů u karcinomu endometria

Ceska Gynekologie

Volumn 75, Issue 3, 2010, Pages 193-199

  Markova I ^a   Pilka, R ^a   Duskova M ^a   Zapletalova J ^a   Kudela, M ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Endometrial cancer; Immunohistochemistry; Prognostic factor; Recurrence

Indexed keywords

TUMOR MARKER;

ADULT; AGED; CHEMISTRY; DISEASE FREE SURVIVAL; ENDOMETRIUM TUMOR; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TUMOR INVASION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 77954847024     PISSN: 12107832     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. World cancer research fund: American Institute for Cancer Research: Food, Nutrition and the Prevention of Cancer: A global Perspective. Washington, DC, 1997.
2. Ascher, SM., Reinhold, C. Imaging of cancer of the endometrium. Radiol Clin North Am, 2002, 40, p. 563-576.
3. Canavan, TP., Doshi, NR. Endometrial cancer. Am Fam Physician, 1999, 59, p. 3069-3077.
4. Erdem, O., Erdem, M., Dursun, A., et al. Angiogenesis, p53, and bcl-2 expression as prognostic indicators in endometrial cancer: comparison with traditional clinicopathologic variables. Int J Gynecol Pathol, 2003, 22, p. 254-260.
5. Ferrandina, G., Ranelletti, FO., Gallotta, V., et al. Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer. Gynecol Oncol, 2005, 98. p. 383-389.
6. Fitzgibbons, PL., Page, DL., Weaver, D., et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med, 2000, 124, p. 966-978.
7. Gates, EJ., Hirschfield, L., Matthews, RP., et al. Body mass index as a prognostic factor in endometrioid adenocarcinoma of the endometrium. J Natl Med Assoc, 2006, 98, p. 1814-1822.
8. Geisler, JP., Geisler, HE., Wiemann, MC., et al. p53 expression as a prognostic indicator of 5-year survival in endometrial cancer. Gynecol Oncol, 1999, 74. p. 468-4671.
9. Geisler, JP., Wiemann, MC., Zhou, Z., et al. p53 as a prognostic indicator in endometrial cancer. Gynecol Oncol, 1996, 61, p. 245-248.
10. Goodman, MT., Wilkens, LR., Hankin, JH., et al. Association of soy and fiber consumption with the risk of endometrial cancer. Am J Epidemiol, 1997, 146, p. 294-306.
11. Halperin, R., Zehavi, S., Habler, L., et al. Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium. Eur J Gynaecol Oncol, 2001, 22, p. 122-126.
12. Inoue, M. Current molecular aspects of the carcinogenesis of the uterine endometrium. Int J Gynecol Cancer, 2001, 11, p. 339-348.
13. Jalava, P., Kuopio, T., Huovinen, R., et al. Immunohistochemical staining of estrogen and progesterone receptors: aspects for evaluating positivity and defining the cutpoints. Anticancer Res, 2005, 25, p. 2535-2542.
14. Kadar, N., Malfetano, JH., Homesley, HD. Steroid receptor concentrations in endometrial carcinoma: effect on survival in surgically staged patients, Gynecol Oncol, 1993, 50, p. 281-286.
15. Kodama, S., Kase, H., Tanaka, K., et al. Multivariate analysis of prognostic factors in patients with endometrial cancer. Int J Gynaecol Obstet, 1996, 53, p. 23-30.
16. Lax, SF., Pizer, ES., Ronnett, BM., et al. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression. Hum Pathol, 1998, 29, p. 551-558.
17. Lu, KH., Broaddus, RR. Gynecologic cancers in Lynch syndrome/HNPCC. Fam Cancer, 2005, 4, p. 249-254.
18. Lukes, AS., Kohler, MF., Pieper, CF., et al. Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer. Cancer, 1994, 73, p. 2380-2385.
19. Maneschi, M., Maneschi, F., Geraci, P., et al. Surgical pathological staging of endometrial carcinoma and results of treatment. Eur J Gynaecol Oncol, 1992, 13, p. 30-35.
20. Mariani, A., Sebo, TJ., Webb, MJ., et al. Molecular and histopathologic predictors of distant failure in endometrial cancer. Cancer Detect Prev, 2003, 27, p. 434-441.
21. Morris, PC., Anderson, JR., Anderson, B., et al. Steroid hormone receptor content and lymph node status in endometrial cancer. Gynecol Oncol, 1995, 56, p. 406-411.
22. Morrison, C., Zanagnolo, V., Ramirez, N., et al. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. J Clin Oncol, 2006, 24, p. 2376-2385.
23. Morrow, CP., Bundy, BN., Kurman, RJ., et al. Relationship between suigical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol, 1991, 40, p. 55-65.
24. Ogawa, Y., Moriya, T., Kato, Y., et al. Immunohistochemical assessment for estrogen receptor and progesterone receptor status in breast cancer: analysis for a cut-off point as the predictor for endocrine therapy. Breast Cancer, 2004, 11, p. 267-275.
25. Ohkouchi, T., Sakuragi, N., Watari, H., et al. Prognostic significance of bcl-2, p53 overexpression, and lymph node metastasis in surgically staged endometrial carcinoma. Am J Obstet Gynecol, 2002, 187, p. 353-359.
26. Owen, P., Duncan, ID. Is there any value in the long term follow up of women treated for endometrial cancer? Br J Obstet Gynaecol, 1996, 103, p. 710-713.
27. Pijnenborg, JM., van de Broek, L., Dam de Veen, GC., et al. TP53 overexpression in recurrent endometrial carcinoma. Gynecol Oncol, 2006, 100, p. 397-404.
28. Pisani, AL., Barbuto, DA., Chen, D., et al. HER-2/neu, p53, and DNA analyses as prognosticators for survival in endometrial carcinoma. Obstet Gynecol, 1995, 85, p. 729-734.
29. Podczaski, E., Kaminski, P., Gurski, K., et al. Detection and patterns of treatment failure in 300 consecutive cases of "early" endometrial cancer after primary surgery. Gynecol Oncol, 1992, 47, p. 323-327.
30. Rose, PG. Endometrial carcinoma. N Engl J Med, 1996, 335, p. 640-649.
31. Sakuragi, N., Ohkouchi, T., Hareyama, H., et al. Bcl-2 expression and prognosis of patients with endometrial carcinoma. Int J Cancer, 1998,79, p. 153-158.
32. Salvesen, HB., Akslen, LA., Albrektsen, G., et al. Poorer survival of nulliparous women with endometrial carcinoma. Cancer, 1998, 82, p. 1328-1333.
33. Salvesen, HB., Iversen, OE., Akslen, LA. Identification of highrisk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas. Clin Cancer Res, 1998, 4, p. 2779-2785.
34. Salvesen, HB., Iversen, OE., Akslen, LA. Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study. J Clin Oncol, 1999, 17, p. 1382-1390.
35. San tin, AD., Bellone, S., Roman, JJ., et al. Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu, Int J Gynaecol Obstet, 2008, 102, p. 128-131.
36. ÚZIS, Novotvary CR, 2005.
37. Yamauchi, N., Sakamoto, A., Uozaki, H., et al. Immunohistochemical analysis of endometrial adenocarcinoma for bcl-2 and p53 in relation to expression of sex steroid receptor and proliferative activity. Int J Gynecol Pathol, 1996, 15, p. 202-208.
38. Zaino, RJ., Kurman, R., Herbold, D., et al. The significance of squamous differentiation in endometrial carcinoma. Data from a Gynecologic Oncology Group study. Cancer, 1991, 68, p. 2293-2302.
39. Zaino, RJ., Kurman, RJ., Diana, KL., et al. Pathologic models to predict outcome for women with endometrial adenocarcinoma: the importance of the distinction between surgical stage and clinical stage - a Gynecologic Oncology Group study. Cancer, 1996, 77, p. 1115-1121.